Sonoma Biotherapeutics Raises $265M to Advance Therapies for Autoimmune, Inflammatory Diseases

Sonoma Biotherapeutics has raised $265 million in new funding which will be used to advance its programs aiming to treat autoimmune and inflammatory conditions such as rheumatoid arthritis, type 1 diabetes, and IBD.